April 5 (Reuters) - A UK court on Wednesday ordered GSK's Tesaro to pay rival AstraZeneca (AZN.L) royalties on total sales of ovarian cancer drug Zejula, in a win for the Anglo-Swedish drugmaker.
Affinivax hires Merck's Vaxneuvance leader for rival vaccine. Epizyme's CEO leaves post to former Tesaro exec. BD hires 22-year J&J veteran as CFO.
With Tesaro staff and expertise in the mix, GSK gears up for 3 oncology launches in 2020
After the PARP inhibitor showdown at ESMO this weekend between GlaxoSmithKline’s Zejula and AstraZeneca and Merck & Co.’s Lynparza, industry watchers declared it difficult to tell who won this round of the data battle. But another company should definitely feel the pressure, analysts say, and that's Clovis Oncology.
When it comes to selecting patients for PARP inhibitors, mutations in the BRCA1 and BRCA2 genes have been the go-to biomarker, the surest way of finding those most likely to benefit from the therapy. But AstraZeneca and Merck are making some headway in carving out a new niche for itself in prostate cancer.
Quietly, and without the fanfare of gene and cell therapies, PARP inhibitors from the likes of AstraZeneca, Merck and GlaxoSmithKline's Tesaro have been racking up big trial wins in breast, ovarian and other cancers.
Hal Barron has detailed efforts to embolden GlaxoSmithKline scientists to take “smart risks” when developing drugs. The culture change is part of an effort to stop the fear of failure from pushing GSK researchers to make conservative decisions.
GlaxoSmithKline laid out $5.1 billion last year for Tesaro and its key PARP inhibitor, Zejula, and with some new ovarian cancer data, it has another chance to prove the deal was worth it—and a shot at a piece of the market that AstraZeneca and Merck's Lynparza hasn't already staked out for itself.
German biotech Evotec has decided to bundle its cancer therapeutic programmes focused on DNA damage response (DDR) into a new spin-off company.
Carrick Therapeutics is shifting its center of gravity toward the U.S. The Anglo-Irish cancer biotech has appointed ex-Tesaro CFO Tim Pearson to lead the company from its new site in Boston.